±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 2286  |  »Ø¸´: 12
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

yalefield

½ð³æ (ÎÄ̳¾«Ó¢)

ÀϺºÒ»Ã¶

[½»Á÷] ÏÈÉùÒ©ÒµµÄ¶÷¶È£¨ENDOSTAR£©[ת]

×÷ÕߣºJingyi

¡¡¡¡2007Äê³õ£¬ÖйúµÄÒ»¼ÒÖÆÒ©¹«Ë¾ÏÈÉùÖÆÒ©ÔÚŦԼÉÏÊС£ÆäÖ÷Òª²úÆ·ÊÇ¡°¶÷¶È¡±(ENDOSTAR)£¬Ò»ÖÖÒÖÖÆÑª¹ÜÉú³¤µÄÒ©ÎÖ÷ÒªÕë¶Ô·ÇСϸ°û·Î°©(NSCLC)¡£ÕâÊÇÒ»Öַdz£ÆÕ±éµÄ¶ñÐÔÖ×Áö£¬¾­³£ÓÉÎüÑÌÓÕ·¢¡£

¡¡¡¡¼ÇµÃÒÔǰ¿´¹ýһЩÎÄÕ£¬½éÉÜͨ¹ýÒÖÖÆÑª¹ÜÉú³¤¡°¶öËÀ¡±°©Ï¸°û¡£Ã»Ïëµ½ÏÖÔÚÒѾ­³ö²úÆ·£¬¶øÇÒÊÇÕë¶ÔÖйú·Ç³£ÆÕ±éµÄ·Î°©¡£¿Éϲ¿ÉºØ¡£

¡¡¡¡µ«ÊÇ×ÐϸÑо¿Ò»Ï£¬È´·¢ÏÖÎÊÌâ¡£

    ¶÷¶ÈµÄÖ÷Òª³É·Ö(Endostatin)ÔÚ¹úÍâµÄ¶þÆÚÁÙ´²Öб»Åж¨Ã»ÓÐÃ÷ÏÔЧ¹û¡£(Note 1) µ±³õÑо¿¸ÃÒ©µÄÒ»¼ÒÃÀ¹úÉú»¯¹«Ë¾EntreMed¼¸ºõÆÆ²ú¡£²Æ¸»ÔÓÖ¾ÆÀÂÛ˵£¬¸ÃÒ©¡°Ï·¾çÐÔµÄʧ°ÜÁË¡±¡£(Note 2)
    µ«ÊÇ£¬¸Ã¹«Ë¾ÔÚÖйú×öµÄ493ÀýÈ´·¢ÏÖʹÓö÷¶È¿ÉÒÔʹ1ÄêÉú´æÂÊ´Ó31%Ôö¼Óµ½63%£¬Æ½¾ùÉú´æÊÙÃüÊǶÔÕÕ×éµÄ5±¶¡£(Note 3£©¡£

¡¡¡¡ÏÖÔÚ¶÷¶ÈÒѾ­ÔÚÖйú500¶à¼ÒҽԺʹÓã¬ÓÃÓÚÖÎÁÆÖйú´óÁ¿ÒòÎüÑ̶øµÃ·Î°©µÄ²¡ÈË¡£ºÜÆæ¹ÖΪʲô¹úÄÚÍâµÄÁÙ´²½á¹û²îÒìÕâô´ó¡£ÓÐûÓÐÄÄλרҵÈËÊ¿Ñо¿Ò»Ï¡£

Note:
1. Kulke M H et al (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24: 3555-3561.
2. http://yalemedicine.yale.edu/ym_sp06/booksideas.html
3. Company Prospectus - Strong Growth Potential of Our Innovative Pharmaceutical Endu
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

WANTTOKNOW

Òø³æ (ÖøÃûдÊÖ)

¶ÔÓÚ°©Ö¢£¬¼ÙÒ©ÕæÒ©¶¼Êǻƽð¼Û£»

½á¹ûÊÇ»¼ÕßÈ˲ÆÁ½¿Õ¡£
7Â¥2008-01-17 17:16:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 13 ¸ö»Ø´ð

wangw2008

½ð³æ (Ö°Òµ×÷¼Ò)

´¿½àÔÚ¼ËÔº,¶éÂäÔÚ½ÌÓý²¿.

±¾ÈËÒ²Ò»Ö±ÔÚ»³ÒÉÕâ¸öÊý¾Ý£¬ÏÈÉùµÄËÄÆÚÁÙ´²Êý¾Ý×öµÄºÜ²î£¬ÖÁÓÚ£±£¬£²ÆÚµÄÊý¾ÝÔõôÀ´µÄ£®´ó¸ÅÖ»ÓÐÖйúµÄÕâ¸ö»·¾³Ï²Żá³öÏÖ£®
ÑÏÕýÉùÃ÷: ±¾ÌûÄÚÈÝÎ´Éæ¼°¹¥»÷ÈκγæÓÑ(°üÀ¨ÒÔָɣÂî»±£¬º¬É³ÉäÓ°µÈÐÎʽ),²»Ó°ÏìºÈѪ(ɽ¶«»°ºÍг)
2Â¥2007-12-19 07:07:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

¶¹¸ç

Ö÷¹ÜÇø³¤ (Ö°Òµ×÷¼Ò)

ÖÆÁ£ÄÜÊÖ

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

ÕâÑùµÄ»°Ò©ÎïûÓÐÁÆÐ§ÔõôÄÜÒ»Ö±ÔÚÁÙ´²ÉÏÓÃÄØ£¿
±ßѧ±ßÎÊ£¬²ÅÓÐѧÎÊ¡£
3Â¥2007-12-19 14:00:23
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
4Â¥2007-12-19 14:13:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0703µ÷¼Á +9 ʰ¾ÁÒ¼ 2026-04-04 10/500 2026-04-04 22:53 by ÀíÏëÔÚʵ¼ùÖ®ÖÐ
[¿¼ÑÐ] 086000ÉúÎïÓëÒ½Ò©298µ÷¼ÁÇóÖú +6 ÔªÔªÇàÇà 2026-03-31 8/400 2026-04-04 22:15 by lys0704
[¿¼ÑÐ] Ò»Ö¾Ô¸°²»Õij211 0703»¯Ñ§×Ü·Ö339Çóµ÷¼Á +6 Íí·ç²»Íí 2026-04-04 6/300 2026-04-04 20:11 by dongzh2009
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +5 ´Þwj 2026-03-31 5/250 2026-04-04 19:45 by 1753564080
[¿¼ÑÐ] 11408 Ò»Ö¾Ô¸Î÷µç£¬277·ÖÇóµ÷¼Á +4 zhouzhen654 2026-04-03 4/200 2026-04-04 18:10 by Öí»á·É
[¿¼ÑÐ] Ò»Ö¾Ô¸C9µÄ»¯Ñ§¹¤³Ì£¨085602£© 340·Ö£¬¸Ð¾õУÄÚµ÷¼ÁÎÞÍû£¬Çóµ÷¼Á +9 ÍòÊÂÒËÕé 2026-04-04 9/450 2026-04-04 11:49 by à£à£à£0119
[¿¼ÑÐ] 334Çóµ÷¼Á +8 ÔøÑöÖ® 2026-04-03 8/400 2026-04-04 11:16 by w_xuqing
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¿Æ¼¼´óѧ²ÄÁϹ¤³Ì085601£¬Çóµ÷¼Á +17 cdyw 2026-04-02 18/900 2026-04-04 11:14 by w_xuqing
[¿¼ÑÐ] Çóµ÷¼Á +3 wos666 2026-04-03 3/150 2026-04-04 05:16 by gswylq
[¿¼ÑÐ] 265Çóµ÷¼Á +17 ÁÖÉîÎÂÀ½ 2026-04-01 20/1000 2026-04-04 01:09 by userper
[¿¼ÑÐ] 292Çóµ÷¼Á +21 ÊÇåû×ÓÒ²ÊÇÑÐ×Ó 2026-03-30 22/1100 2026-04-03 21:44 by qlm5820
[¿¼ÑÐ] 312Çóµ÷¼Á +6 ССī123 2026-04-02 7/350 2026-04-03 07:32 by jsw79
[¿¼²©] É격ÇóÖú +3 Reee1Llll 2026-04-01 3/150 2026-04-02 22:29 by ÕâÊÇÒ»¸öÎÞÁĵÄê
[¿¼ÑÐ] »¯Ñ§070300-×Ü·Ö378-Çóµ÷¼Á +5 ŲÒÎ×ÓµÄÅÝÅÝÌÇ 2026-04-02 5/250 2026-04-02 22:20 by ZXlzxl0425
[¿¼ÑÐ] 0805Çóµ÷¼Á +8 ÊÇË®·Ö 2026-03-31 8/400 2026-04-02 10:46 by guanxin1001
[¿¼ÑÐ] Çó0861½»Í¨ÔËÊäר˶or²ÄÁÏר˶µ÷¼Á +4 ÀÕ²¼ÀÊ@ 2026-03-31 4/200 2026-04-01 09:54 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸±±ÁÖʳƷÓëÓªÑø095500£¬301·Ö£¬ÒѹýÁù¼¶£¬ÓпÆÑо­Àú +4 ¿ìÀÖ´¢Ðî¹Þ 2026-03-31 4/200 2026-04-01 09:26 by JourneyLucky
[¿¼ÑÐ] µ÷¼ÁÉêÇë +8 ÕÅÕÅÕÅÕÅzy 2026-03-31 9/450 2026-04-01 08:29 by zjbkx
[¿¼ÑÐ] Ò»Ö¾Ô¸Öк£Ñó²ÄÁÏ357 +4 Âó¶÷Àò. 2026-03-30 4/200 2026-03-31 14:35 by ¼Çʱ¾2026
[¿¼ÑÐ] ÉúÎÑÐ337·ÖÇóµ÷¼Á +4 cgxin 2026-03-30 6/300 2026-03-31 14:18 by ¼Çʱ¾2026
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û